interferon beta + interferon gamma + tamoxifen

A combination therapy consisting of interferon beta, interferon gamma, and tamoxifen that has been studied for its potential synergistic antitumor effects in treating breast cancer. This combination appears to work through enhanced antiproliferative effects and upregulation of interferon-stimulated genes. Research has shown that tamoxifen can enhance interferon-regulated gene expression in breast carcinoma cell lines. When combined with interferon-beta, tamoxifen enhances the expression of several interferon-beta-inducible genes in human breast cancer cells, which occurs at the transcriptional level. This enhancement appears to be independent of estrogen receptor status. Studies have demonstrated that the combination of interferon-beta and tamoxifen can produce synergistic antitumor effects. In experimental models using MCF-7 and NIH-OVCAR-3 tumors, established tumors regressed when treated with the combination, while single-agent therapy was ineffective. The mechanism behind this synergy involves tamoxifen's ability to enhance interferon-stimulated gene expression. When tamoxifen is combined with either interferon-beta or interferon-gamma, it enhances the transcriptional induction of interferon-regulated promoters. Specifically, in tamoxifen-treated cells, both interferon-beta and interferon-gamma readily activate transcription factors ISGF-3 and GAF, respectively.